share_log

Allarity Therapeutics | SC 13G: Statement of acquisition of beneficial ownership by individuals-Streeterville Capital LLC(14.7%),Streeterville Management LLC(14.7%), etc.

Allarity Therapeutics | SC 13G: Statement of acquisition of beneficial ownership by individuals-Streeterville Capital LLC(14.7%),Streeterville Management LLC(14.7%), etc.

Allarity Therapeutics | SC 13G：超過5%持股股東披露文件-Streeterville Capital LLC(14.7%),Streeterville Management LLC(14.7%)等
美股SEC公告 ·  08/30 04:01
牛牛AI助理已提取核心訊息
Streeterville Capital LLC, along with Streeterville Management LLC and John M. Fife, have filed a Schedule 13G with the SEC, indicating a significant ownership stake in Allarity Therapeutics Inc. The filing, dated August 19, 2024, reports that Streeterville Capital LLC directly owns 8,999,800 shares of Allarity Therapeutics' common stock, representing 14.7% of the company's class of securities. John M. Fife, a U.S. citizen, is identified as the person with the authority to receive notices and communications regarding this ownership. The shares provide Streeterville Capital LLC with sole voting power and sole dispositive power over 2,114,737 shares. The filing asserts that the securities were acquired in the ordinary course of business and not with the purpose of changing or influencing the control of the issuer.
Streeterville Capital LLC, along with Streeterville Management LLC and John M. Fife, have filed a Schedule 13G with the SEC, indicating a significant ownership stake in Allarity Therapeutics Inc. The filing, dated August 19, 2024, reports that Streeterville Capital LLC directly owns 8,999,800 shares of Allarity Therapeutics' common stock, representing 14.7% of the company's class of securities. John M. Fife, a U.S. citizen, is identified as the person with the authority to receive notices and communications regarding this ownership. The shares provide Streeterville Capital LLC with sole voting power and sole dispositive power over 2,114,737 shares. The filing asserts that the securities were acquired in the ordinary course of business and not with the purpose of changing or influencing the control of the issuer.
Streeterville Capital LLC與Streeterville Management LLC和John m. Fife一起向SEC提交了一份13G表格，表明其在Allarity Therapeutics Inc.擁有重要的股權。文件日期爲2024年8月19日，報告稱Streeterville Capital LLC直接持有Allarity Therapeutics的普通股8,999,800股，佔公司證券類別的14.7%。 John m. Fife是美國公民，被認定爲接收與此所有權相關的通知和通信的人。這些股份使得Streeterville Capital LLC對2,114,737股擁有唯一的表決權和唯一的處置權。該申報聲稱這些證券是在日常業務中獲得的，而不是爲了改變或影響發行人的控制權。
Streeterville Capital LLC與Streeterville Management LLC和John m. Fife一起向SEC提交了一份13G表格，表明其在Allarity Therapeutics Inc.擁有重要的股權。文件日期爲2024年8月19日，報告稱Streeterville Capital LLC直接持有Allarity Therapeutics的普通股8,999,800股，佔公司證券類別的14.7%。 John m. Fife是美國公民，被認定爲接收與此所有權相關的通知和通信的人。這些股份使得Streeterville Capital LLC對2,114,737股擁有唯一的表決權和唯一的處置權。該申報聲稱這些證券是在日常業務中獲得的，而不是爲了改變或影響發行人的控制權。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。